TY - JOUR
T1 - Cholesterol levels of Japanese dyslipidaemic patients with various comorbidities
T2 - BioBank Japan
AU - BioBank Japan Cooperative Hospital Group
AU - Yokomichi, Hiroshi
AU - Noda, Hokuto
AU - Nagai, Akiko
AU - Hirata, Makoto
AU - Tamakoshi, Akiko
AU - Kamatani, Yoichiro
AU - Kiyohara, Yutaka
AU - Matsuda, Koichi
AU - Muto, Kaori
AU - Ninomiya, Toshiharu
AU - Kubo, Michiaki
AU - Nakamura, Yusuke
AU - Yamagata, Zentaro
AU - Misumi, Kazuo
AU - Iha, Kiyoshi
AU - Matsubayashi, Sunao
AU - Matsuura, Kei
AU - Minami, Shiro
AU - Sugihara, Hitoshi
AU - Kodani, Eitaro
AU - Tamura, Naoto
AU - Matsushita, Masakazu
AU - Gotoh, Akihiko
AU - Asai, Satoshi
AU - Moriyama, Mitsuhiko
AU - Takahashi, Yasuo
AU - Fujioka, Tomoaki
AU - Obara, Wataru
AU - Mori, Seijiro
AU - Ito, Hideki
AU - Nagayama, Satoshi
AU - Miki, Yoshio
AU - Masumoto, Akihide
AU - Yamada, Akira
AU - Nishizawa, Yasuko
AU - Kodama, Ken
AU - Ugi, Satoshi
AU - Maegawa, Hiroshi
AU - Koretsune, Yukihiro
AU - Kusuoka, Hideo
AU - Okumura, Masao
N1 - Publisher Copyright:
© 2017 The Authors.
PY - 2017
Y1 - 2017
N2 - Background: Controlling serum cholesterol is critical to prevent cardiovascular disease in patients with dyslipidaemia. Guidelines emphasise the need to select treatment for dyslipidaemia based on specific patient profiles; however, there is little information about the serum cholesterol levels of patients in each profile in Japan. Therefore, we aimed to describe the serum cholesterol levels and prevalence of uncontrolled cases in Japanese patients with dyslipidaemia. Methods: We included data for patients with dyslipidaemia between 2003 and 2007 from the BioBank Japan Project (66 hospitals). Then, we reported their serum cholesterol levels by age, body mass index, glycaemic control (glycated haemoglobin A1c), blood pressure, smoking, drinking, comorbidity and medication profiles. Results: We included 22,189 male and 21,545 female patients. The mean serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and non-HDL-C levels in males were 117.4 mg/dL, 51.0 mg/dL, 187.6 mg/dL and 153.6 mg/dL, respectively; the corresponding levels in females were 129.5 mg/dL, 60.5 mg/dL, 144.9 mg/dL and 157.9 mg/dL, respectively. In both males and females, the LDL-C levels were the highest in the following profiles: age 19e44 years, body mass index 18.5e22 kg/m2, glycated haemoglobin A1c < 6.0%, never smoker, chronic respiratory disease as a comorbidity and no medication use. Conclusions: These data provide details of serum cholesterol levels by risk-factor profile in patients with dyslipidaemia and could add evidence of treatment decisions.
AB - Background: Controlling serum cholesterol is critical to prevent cardiovascular disease in patients with dyslipidaemia. Guidelines emphasise the need to select treatment for dyslipidaemia based on specific patient profiles; however, there is little information about the serum cholesterol levels of patients in each profile in Japan. Therefore, we aimed to describe the serum cholesterol levels and prevalence of uncontrolled cases in Japanese patients with dyslipidaemia. Methods: We included data for patients with dyslipidaemia between 2003 and 2007 from the BioBank Japan Project (66 hospitals). Then, we reported their serum cholesterol levels by age, body mass index, glycaemic control (glycated haemoglobin A1c), blood pressure, smoking, drinking, comorbidity and medication profiles. Results: We included 22,189 male and 21,545 female patients. The mean serum low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG) and non-HDL-C levels in males were 117.4 mg/dL, 51.0 mg/dL, 187.6 mg/dL and 153.6 mg/dL, respectively; the corresponding levels in females were 129.5 mg/dL, 60.5 mg/dL, 144.9 mg/dL and 157.9 mg/dL, respectively. In both males and females, the LDL-C levels were the highest in the following profiles: age 19e44 years, body mass index 18.5e22 kg/m2, glycated haemoglobin A1c < 6.0%, never smoker, chronic respiratory disease as a comorbidity and no medication use. Conclusions: These data provide details of serum cholesterol levels by risk-factor profile in patients with dyslipidaemia and could add evidence of treatment decisions.
KW - Cardiovascular diseases
KW - Comorbidity
KW - Dyslipidaemia
KW - Low-density lipoprotein cholesterol
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85016439475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016439475&partnerID=8YFLogxK
U2 - 10.1016/j.je.2016.12.014
DO - 10.1016/j.je.2016.12.014
M3 - Article
C2 - 28196738
AN - SCOPUS:85016439475
SN - 0917-5040
VL - 27
SP - S77-S83
JO - Journal of epidemiology
JF - Journal of epidemiology
IS - 3
ER -